

Erratum to: Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal

Herbert Lerner · Joyce Whang · Rebecca Nipper

Published online: 26 January 2013
© Springer Science+Business Media New York 2013

Erratum to: Surg Endosc
DOI 10.1007/s00464-012-2724-3

On the second page, second paragraph, fourth to fifth line, add the word “information” after “additional”.

On that same page, right column, second paragraph, second line, add the word “be” after “would”.

On the same page, right column, last paragraph, seventh line, delete the phrase “shifted to recommending has”.

The online version of the original article can be found under doi:[10.1007/s00464-012-2724-3](https://doi.org/10.1007/s00464-012-2724-3).

H. Lerner · J. Whang · R. Nipper
Center for Devices and Radiological Health, Office of Device Evaluation, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA

H. Lerner (✉)
Division of Reproductive, Gastro-Renal and Urological Devices, FDA/CDRH/ODE, WO66 Room G114, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002, USA
e-mail: Obesitydevice@fda.hhs.gov